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Background:Many trials have shown that statins can reduce plaque volume (PV) associated with the degree of
LDL-C reduction.
The goal of this study is to determine whether the combination of ezetimibe and a statin produces greater
reductions in coronary plaque volume compared to statin monotherapy in patients with acute coronary
syndrome (ACS).
Methods: Prospective serial intravascular ultrasound (IVUS) of non-culprit lesions of the target vessel was
performed in 95 patients with ACS. Of these, 50 patients were administered combination of atorvastatin
20 mg/day and ezetimibe 10 mg/day. 45 subjects treated by atorvastatin 20 mg/day alone were the control
group. At the beginning and 24 weeks after PCI, quantitative PV was accessed by IVUS. The primary end point
was the percentage change in non-culprit coronary PV.
Results: LDL-C was signiﬁcantly decreased by 49.8% in the ezetimibe/atorvastatin group compared with 34.6% in
the atorvastatin group. Signiﬁcant regression of plaque volumewas observed from baseline to follow-up in both
groups. The percentage changes in PV were greater in the ezetimibe/atorvastatin group than in the atorvastatin
alone group (12.5% versus 7.6%, p = 0.06), but statistically not signiﬁcant. In 34 diabetic patients, regression of
PV was signiﬁcantly greater in the ezetimibe/atorvastatin group than in the statin alone group (13.9% versus
5.1%, p = 0.04) and % change of PV signiﬁcantly correlated with LDL-C reduction.
Conclusions: Additional LDL-C reduction with combination therapy tended to reduce more plaque regression
compared to a statin alone in patients with ACS. In diabetic patients, further reduction of LDL-C was associated
with a signiﬁcantly greater reduction in PV.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
A large amount of evidence was accumulated that statins can reduce
major adverse cardiovascular events associated with reduced degree
of LDL-C [1–3]. Intravascular ultrasound (IVUS) trials demonstrated
that aggressive LDL-C lowering could reduce plaque volume (PV) and
stabilize the unstable plaque [4–7]. It was also demonstrated that the
magnitude of reduction in LDL-C correlated with plaque regressionascularMedicine, 2-1-1 Hongo,
ax: +81 3 5689 0627.
.
and Ltd. This is an open access articleafter statin treatment. These IVUS studies suggested that the beneﬁcial
effect of intensive lipid lowering treatment on plaque regression in
patients with chronic coronary artery disease (CAD) is also found in
patients with acute coronary syndrome (ACS) [8–10]. Thus, reduction
in LDL-C can not only decrease cardiovascular events, but also retard
PV. However, new AHA/ACC guidelines demonstrated that evidence
supports high-intensity statin therapy for secondary prevention group
and it does not support the use of an LDL-C target. As of yet, there
are no data to show that adding non-statin drugs to high-dose statin
therapy will provide incremental risk reduction beneﬁt. The goal of
this study was to determine whether combination therapy of ezetimibe
and a statinwas superior to a statin alone in reducing PV in patientswith
ACS undergoing successfully percutaneous coronary intervention (PCI).under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
9N. Nakajima et al. / IJC Metabolic & Endocrine 3 (2014) 8–132. Methods
The ZEUS (eZEtimibe Ultrasound Study) is a non-randomized, open
label trial designed to assess the regression of PV resulting from
the treatment with atorvastatin and ezetimibe in patients with ACS.
All patients enrolled in this study received atorvastatin 20 mg and
ezetimibe 10 mg. IVUS examination was performed at baseline and
then repeated 6 months after treatment. Inclusion criteria were
patients with ACS and 20 to b79 years old (at the time of giving
consent) who had emergency PCI in a culprit lesion and untouched
non-culprit target lesion of less 25% stenosis that could be imaged
by IVUS. Exclusion criteria were failed PCI, recommended CABG,
and administration of lipid-lowering drugs (statin, ﬁbrate, probucol
or analog, nicotinic acid, or other prohibited drugs) before enrollment.
Patients with renal failure (Scr N 2.0 mg/dL), moderate or severe
congestive heart failure, diseased bypass graft, and left main coronary
artery occlusion of 50% or more were also excluded. Included patients
were found to have coronary plaques (N500 μm in thickness, or percent
plaque area ≥20%) in the culprit vessel at least 5 mm away from the
PCI-treated lesions. First, we collected the patients from our previous
IVUS study database [11]. Of these patients, 45 patients with ACS and
treated by atorvastatin 20 mg alone were selected according to the
restricted criteria mentioned here. These patients were put into the
control group. The entry criteria and protocol of the two groups were
similar; the main difference was that the ZEUS trial included only
patients who were treated by ezetimibe and atorvastatin. The control
group enrolled atorvastatin only.
Blood sampleswere obtained at baselinewithin 72 h after PCI before
administration of either a statin or ezetimibe and at 6 month follow-up.
The lipid proﬁle and other biomarkers were measured at SRL Co., Ltd.,
Tokyo, Japan. ACS was deﬁned as high-risk unstable angina pectoris
(UAP), non-ST-elevated myocardial infarction (MI) or ST-elevated MI.
An increase (≥2-fold) in serum creatine phosphokinase or troponin T
positivity indicated a diagnosis of MI. High-risk UAP was deﬁned in
patients with resting or worsening chest pain that was persistent
(≥20 min) along with any of the following ﬁndings: ST-segment de-
pression of ≥0.5 mm or T-wave inversion of ≥3 mm. Diabetes patients
were deﬁned as demonstrating any one of the following: 1) Fasting
plasma glucose level N126 mg/dL, 2) plasma glucose N200 mg/dL 2 h
after a 75 g oral glucose load as in a glucose tolerance test, 3) symptoms
of hyperglycemia and casual plasma glucose N200 mg/dL, and 4)
glycated hemoglobin N6.5% (NGSP (National Glycohemoglobin
Standardization Program) criteria).
The studywas approved by the ethical committees of each participat-
ing institutions. All patients signed informed consent before the study
entry. In total, 95 patients were studied in this analysis, comprising of
45 patients enrolled in the previous trial who were treated with atorva-
statin 20 mg/day between November 2001 and July 2008 and 50 pa-
tients enrolled in the ZEUS trial treated with atorvastatin 20 mg and
ezetimibe 10 mg between September 2008 and December 2009. These
studies were conducted in accordance with the ‘Declaration of Helsinki’.
2.1. Intravascular ultrasound procedure and examination
Image analysis was performed by two experienced readers who
reached consensus for each scan at the central core-laboratory. All
scans available for each subject were reviewed simultaneously but
readers were blinded to any corresponding temporal or clinical infor-
mation about the scans or subjects. A single lesion in a non-PCI site
with a reproducible index side branch on the PCI vessel was investigat-
ed in each subject. The assessment sitewas selected at least 5mmto the
PCI site. Details of the IVUS procedure are published elsewhere [9,10]. In
summary, a 40-MHz IVUS catheter (Atlantis SR Pro2Boston Scientiﬁc,
Natick, USA) was used and advanced into the target vessel after
200 μg of intracoronary nitroglycerin, and a motorized pullback device
withdrew the transducer at the speed of 0.5 mm/s. The consolesused were ClearView or Galaxy 2 systems (Boston Scientiﬁc). The
same imaging system with the same type of IVUS catheter was used
for both the baseline and the follow-up examination. The target seg-
ment for analysis was identiﬁed at a non-PCI site of the culprit vessel
based on some reproducible indices. Manual tracing was performed in
every 0.3 mm cross-section and the software (echoPlaque2, INDEC
Systems Inc., Santa Clara, USA) automatically interpolated the tracings
of 15 cross-sections between two manually traced images. A lesion
meeting any of these criteriawas not investigated: calciﬁcation, kinking,
chronic complete occlusion, bypass graft site, site of coronary
atherectomy before PCI, location at the left main trunk, thin
small vessel (b2.0 mm), or location of distal protection device.
The primary end point was the percent change in coronary PV dur-
ing the observation period. Coronary PV was calculated as the sum of
the differences between the external elastic membrane (EEM) and
lumen area across all evaluated frames. The percent change in PV was
deﬁned as the change in PV (follow-up minus baseline PV) divided by
the baseline PV.
2.2. Deﬁnition of events and follow-up for major adverse events
Follow-up visits were scheduled every 2 months. Major adverse
events were deﬁned as all cause death, non-fatal ACS, target vessel
revascularization, and stroke.
2.3. Sample size calculation and data analysis
Mean % change in PV was−13.1 ± 12.8% (SD) in the atorvastatin
group in the ESTABLISH study during 6 month follow-up. In the ZEUS,
LDL-C by ezetimibe in addition to atorvastatin was expected to show
15% more reduction compared to atorvastatin alone. Theoretical %
change in PV was 19.7% using atorvastatin + ezetimibe if a constant
rate of % change in coronary PV of LDL-C reduction was assumed.
Mean and standard deviation of the % change in coronary PV in patients
receiving atorvastatin + ezetimibe were assumed to be superior to
those of atorvastatin alone. 40 patients were needed to permit us to de-
tect a 6.6% reduction in coronary PV with a power of 0.8 and a type 1
error rate of 0.05during the plannedmean follow-up period of half year.
2.4. Statistical analysis
We used the full analysis set (FAS) of the ZEUS for inclusion criteria.
Patients were included in the FAS if they had ACS and measurable IVUS
lesions both at enrollment and at follow-up. Baseline characteristics
were compared for patients in both the ZEUS trial and control group.
Variables of interest at baseline and 6 months in each group were com-
pared. Continuous variables are reported as mean SD. Binary variables
are reported as percentages with 95% conﬁdence intervals. After the
descriptive statistics, comparisons of continuous variables between
the 2 groups were performed by the 2-sample t test or Wilcoxon
rank sum test, and those between the baseline and the follow-up by
1-sample t tests or Wilcoxon sign rank test according to their distribu-
tions. Comparisons of categorical values between the 2 groups were
performed by chi-square tests and Fisher exact tests. We used general
linear models to assess relationships between the % change in coronary
plaque volume and reduction of LDL-C level from baseline to 6 months.
The level of signiﬁcance is p b 0.05 (one-sided) for the analyses.
All statistical analyses were performed by the use of the SAS system
version 9.1 (SAS Institute, Cary, North Carolina).
3. Results
3.1. Baseline characteristics and LDL-C changes
Fig. 1 shows the ﬂow chart of patients through the present trial.
Among 60 ZEUS patients, 2 withdrew consent, IVUS could not be
Total 95 patients
60 Assigned to
receive Atorvastatin
and Ezetimibe
90 Assigned to
receive Atorvastatin
70 patients
6 months follow up
58 patients
6 months follow up
45  Full analysis set50 Full analysis set
2: Lost to follow-up 14: Lost to follow up6: Withdrew consent
2: IVUS not performed
6: IVUS not analysis
7: IVUS not performed
10: IVUS not analysis
8: Not agree in ZEUS
protocol
ZEUS Study Control Group
Fig. 1. Flow of patients through the study.
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IVUS in 6 patients. Therefore, a total of 50 patients had evaluable IVUS
images at both baseline and follow-up. Furthermore, 45 patients from
the control group were selected according to the restricted current
criteria mentioned in the Methods section. A total of 95 patients were
evaluated with paired IVUS during 6 months.
All patients were treated by bare metal stent for culprit lesions.
Baseline characteristics are summarized in Table 1. There were no sig-
niﬁcant differences between the 2 groups in age, gender, body mass
index, hypertension, and type of ACS and the culprit lesion. Antiplatelet
therapy including aspirin and thienopyridineswas used in all patients at
baseline. Furthermore, there were no differences in beta-blocker, ACEI
and ARB use between the groups. Lipid proﬁles (Table 2) were similar
at baseline except for LDL-C/HDL-C, but differed signiﬁcantly at the
end of 6 months of follow-up. In the atorvastatin group, LDL-C was sig-
niﬁcantly reduced from 114.2 to 70.3 mg/dL. In the combination group,
further LDL-C reduction was achieved reaching 56.8 mg/dL. LDL-C atTable 1
Baseline characteristics.
Atorvastatin
(n = 45)
Atorvastatin +
ezetimibe (n = 50)
p
Age (years) 60.7 ± 10.5 63.7 ± 12.6 0.21
Gender (male) 84.4 80.0 0.57
BMI 25.0 ± 3.7 23.5 ± 3.5 0.04
Diabetes (%) 40.0 32.0 0.42
Hypertension (%) 68.9 70.0 0.91
Family history (%) 31.1 24.0 0.44
Smoking (%) 68.9 64.0 0.61
Type of ACS p = 0.97
STEMI (%) 37.8 40.0
NSTEMI (%) 26.7 26.0
UAP (%) 35.6 34.0
Culprit vessel p = 0.84
RCA (%) 33.3 38.0
LAD (%) 44.5 44.0
LCX (%) 22.2 18.0
Concomitant drugs at discharge
Aspirin 100 100 1
Thienopyridine 100 100 1
ARB/ACEI (%) 62.2 68.0 0.55
CCB (%) 33.3 38.0 0.64
PPAR agonist (%) 8.9 10.0 0.86
Sulfonylurea 15.6 10.0 0.42
β-Blocker (%) 44.4 48.0 0.73
STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial
infarction; UAP, unstable angina pectoris; RCA, right coronary artery; LAD, left anterior
descending; LCX, left circumﬂex branch; ARB, angiotensin receptor blocker; ACE,
angiotensin-converting enzyme; CCB, calcium channel blockers; PPAR, peroxisome
proliferator-activated receptor.follow-up and the change in LDL-C showed signiﬁcant lowering in the
combination group that in the statin alone group.
4. IVUS results
Table 3 shows the IVUS proﬁle at baseline and follow-up. The PV
showed a signiﬁcant regression comparedwith baseline for the combina-
tion group (−8.2 (95% CI:−5.5 to−10.9), p b 0.0001) and atorvastatin
group (−6.2 (95%CI:−3.5 to−8.9), pb 0.0001). The percentage chang-
es in PV were greater in the ezetimibe/atorvastatin group than atorva-
statin alone group (12.5% versus 7.6%, p = 0.06), but statistically not
signiﬁcant. There was statistically signiﬁcant correlation between %
change in PV and % reduction in LDL-C (R = 0.22, p = 0.03). Intra- and
interobserver variability values for measuring plaque area in our study
were 0.99 and 0.98, respectively.
4.1. The differences in LDL-C reduction and plaque change regarding
diabetes
Next, we focused on the differences in plaque change regarding
diabetes or not. In 34 diabetic patients, the LDL-C reduction was 33.9%
in the statin alone group (18 patients) and 58.5% reduction in the com-
bination group (16 patients). In 61 non-diabetic patients, LDL-Cwas de-
creased by 35.1% in the statin only group and 45.7% in the combination
group (Fig. 2A). A more signiﬁcant LDL-C reductionwas achieved in the
combination ezetimibe plus a statin treatment regardless of diabetes.
The % change in PV in patients with or without diabetes was shown in
Fig. 2B. In the non-diabetic group of patients, the % change in PV was
similar between the statin alone and combination groups, approximate-
ly 9.2% and 11.9%, respectively (p = 0.41). In contrast, in the diabetic
patients, the plaque was regressed more in the combination group
than in the statin alone group (13.9% versus 5.1%, p = 0.04). We next
examined the relationship between reduction in LDL-C and % change
in PV in diabetic and non-diabetic patients. A signiﬁcant correlation
between LDL-C reduction and % change in PV during the 6-month
follow-up was observed in diabetic patients, but not seen in non-
diabetic patients (Fig. 3).
4.2. Adverse events
Atorvastatin and ezetimibe were well tolerated during the study.
There was no death, myocardial infarction, and stroke in the study
period. TLR was similar between atorvastatin alone and combination
groups (13.3% versus 12.0%, p = 0.84).
5. Discussion
First, ezetimibe plus a statin achievesmuchmore reduction of LDL-C
level compared to statin monotherapy. Second, early intensive lipid-
lowering therapy using atorvastatin or atorvastatin + ezetimibe in
patients with ACS results in remarkable regression of coronary PV
during 6-month follow-up. Third, additional LDL-C reduction with
atorvastatin + ezetimibe tended to reduce more plaque regression
compared to a statin alone, but statistically not signiﬁcant. However,
in diabetic patients, further reduction of LDL-C using ezetimibe and a
statin is associated with a signiﬁcantly greater reduction in PV.
Comparedwith the atorvastatin alone, ezetimibe in addition to ator-
vastatin achievedmore LDL-C reduction (a difference of−15.4 mg/dL).
This difference resulted in reduced % change in PV, but not statistically
signiﬁcantly different in the primary end point over 6 months. This
result is congruous with the SATURN study [12] in which rosuvastatin
is not superior to atorvastatin in regard to plaque regression although
the rosuvastatin group had lower levels of LDL-C than the atorvastatin
group (62.6 versus 70.2 mg/dL). Our ﬁndings were also compared
with the results of the ENHANCE study [13]. In the ENHANCE study, a
well-controlled randomized trial in another vascular bed, no statistically
Table 2
Laboratory results.
Atorvastatin (n = 45) Atorvastatin + ezetimibe (n = 50) p
Baseline
LDL-C (mg/dL) 114.3 ± 34.0 116.2 ± 24.7 0.75
TG (mg/dL) 117.5 ± 83.5 106.3 ± 49.0 0.42
HDL-C (mg/dL) 45.5 ± 14.2 50.4 ± 13.5 0.08
LDL-C/HDL-C 2.74 ± 1.04 2.49 ± 0.87 0.007
hs-CRP (mg/dL) 0.81 ± 1.90 1.75 ± 2.81 0.08
HbA1c (%) 5.84 ± 1.13 5.79 ± 0.90 0.82
BNP (mg/dL) 113.8 ± 157.4 123.7 ± 203.7 0.81
Follow-up
LDL-C (mg/dL) 70.3 ± 23.6 56.8 ± 19.5 0.003
TG (mg/dL) 126.4 ± 70.2 99.4 ± 39.8 0.03
HDL-C (mg/dL) 48.5 ± 14.2 48.6 ± 17.0 0.99
LDL-C/HDL-C 1.63 ± 0.83 1.23 ± 0.55 b0.001
hs-CRP (mg/dL) 0.12 ± 0.14 0.05 ± 0.03 0.003
HbA1c (%) 5.70 ± 0.82 5.65 ± 0.51 0.72
BNP (mg/dL) 69.7 ± 146.6 64.5 ± 62.5 0.84
Percent change (%) Atorvastatin (n = 45) Atorvastatin + ezetimibe (n = 50) p
% change p value compared to baseline % change p value compared to baseline
LCL-C −34.6 ± 27.3 p b 0.0001 −49.8 ± 19.9 p b 0.0001 0.016
TG 22.8 ± 50.9 p = 0.32 6.4 ± 50.5 p = 0.26 0.14
HDL-C 9.8 ± 33.5 p = 0.08 0.4 ± 53.0 p = 0.40 0.10.
hs-CRP −39.2 ± 14.2 p = 0.04 −88.2 ± 17.1 p = 0.004 0.04
BNP −31.2 ± 28.2 p = 0.0004 47.8 ± 25.1 p = 0.09 0.64
HbA1c −1.4 ± 8.2 p = 0.09 −1.2 ± 8.6 p = 0.18 0.94
Values are mg/dL unless otherwise indicated. Continuous variables were represented by mean ± SD. The last column indicates the comparison of percent change in variables between
atorvastatin and atorvastatin + ezetimibe group.
LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; BNP, brain natriuretic peptide.
11N. Nakajima et al. / IJC Metabolic & Endocrine 3 (2014) 8–13signiﬁcant difference in the mean increase in common carotid artery
intima-media thickness over 24 months was observed between a statin
alone and a statin plus ezetimibe, despite a 41% versus 58% reduction in
LDL-C, respectively.
Another important ﬁnding in the current study was that signiﬁcant
relationship between the percent change in PV and LDL-C level could
be observed in the diabetic patients, and was absent in the non-
diabetic patients. This ﬁnding is consistent with JAPAN-ACS, in which
there was signiﬁcant correlation between LDL-C and plaque regression
in diabetic patients whereas no relationship was observed in non-
diabetic patients [10]. In addition, Arai et al. reported that diabetic
patients with LDL-C b75 had greater plaque regression compared
with patients with LDL-C ≧75 from sub-analysis of JAPAN-ACS [14].
One difference between JAPAN-ACS and the ZEUS is the directions
for a medicine; statin mono-therapy was used in JAPAN-ACS which
resulted in a 42% reduction in LDL in comparison with a 55% reductionTable 3
Volume parameters from IVUS results.
Atorvastatin
(n = 45)
Atorvastatin +
ezetimibe (n = 50)
p
Observation length (mm) 8.1 ± 2.7 10.2 ± 4.4 0.006
Vessel volume (VV) (mm3)
Baseline 164.0 ± 78.7 158.1 ± 91.9 0.74
After 6 months 159.2 ± 76.4 148.3 ± 94.2 0.54
Change in VV −4.8 ± 16.8 −9.8 ± 18.6 0.17
% change in VV −2.0 ± 11.0 −7.4 ± 13.7 0.04
Lumen volume (LV) (mm3)
Baseline 87.5 ± 47.0 83.0 ± 51.3 0.66
After 6 months 88.9 ± 47.4 81.4 ± 55.1 0.48
Change in LV 1.4 ± 14.7 −1.6 ± 13.9 0.32
% change in LV 1.3 ± 14.7 −1.5 ± 13.9 0.32
Plaque volume (PV) (mm3)
Baseline 76.5 ± 43.1 75.1 ± 46.6 0.88
After 6 months 70.3 ± 43.1 66.9 ± 45.6 0.71
Change in PV −6.2 ± 9.1 −8.2 ± 9.5 0.30
% change in PV −7.5 ± 12.6 −12.5 ± 12.6 0.06when using the combination of ezetimibe with atorvastatin in the
ZEUS. The ZEUS extends JAPAN-ACS to a very low level of LDL-C using
combination ezetimibe and atorvastatin.
It is interesting to ﬁnd that plaque response to LDL-C loweringwhen
adding ezetimibe to a statin in patients with diabetes differs from that
in non-diabetic patients. This ﬁnding was keeping up with clinical out-
come studies in which absolute risk reductions in those with CAD plus
diabetes are twice as great as in those with CAD without diabetes
when reducing LDL cholesterol from70 to 40 mg/dL [15]. Thus, patients
with CAD with diabetes would be expected to more reductions in
the absolute risk for events when treated from a LDL cholesterol level
of less than 70 mg/dL. In fact, the rationale for the current National
Cholesterol Education Program is to recommend achieving LDL
cholesterol levels b70 mg/dL as an optional goal for patients with
diabetes with established CAD. Otherwise, in non-diabetic patients,
achieving apparently low LDL-C beyond a certain point by inten-
sive lipid lowering therapy may not necessarily improve status
of atherosclerosis.
The exact mechanism of LDL-C-dependent plaque regression in dia-
betic patients remains uncertain. In general, the presence of diabetes
was associatedwith a greater atherosclerotic burden and amore necrot-
ic and lipid core and calcium content [16,17]. Experimental data suggest
that high glucose potentiates foam cell generation by enhancingmacro-
phage entry into vascular wall and inhibiting cholesterol efﬂux [18].
Retention of ApoB-lipoproteins, cholesterol and other toxic lipids,
and foam cells within the arterial wall was emigrated out of the
arterial wall [19]. As a result, lipid and necrotic core and other com-
ponents of the plaque were removed. In fact, lipid lowering therapy
reduced the lipid core through decreasing the numbers of macro-
phages and proteolytic activity and increasing collagen content of
established atheroma in rabbits [20]. The IVUS study also demon-
strated that statin treatment reduced PV due to absorption of the
lipid core [21]. It can be assumed that some of these mechanisms
are dependent on LDL-C level. These putative pathways provide a
biological rationale for our clinical observation of response of plaque
change to LDL-C in diabetes patients.
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Fig. 2. Percent change in LDL-C (A) and in plaque volume (B) according to treatment without and with diabetic patients. (A) % change in LDL-C during 6-month follow-up period
according to atorvastatin 20 mg/day or combination of ezetimibe 10 mg/day plus atorvastatin 20 mg/day. LDL-C was lower in combination than that in statin alone. Values are
mean ± SE. (B) % change in plaque volume during 6-month follow-up period according to atorvastatin 20 mg/day or combination of ezetimibe 10 mg/day plus atorvastatin
20 mg/day. In diabetic patients, the percent change in PV at the 6-month follow-up was signiﬁcantly lower in combination group compared with statin alone. Otherwise,
in non-diabetic patients, no difference was seen in PV reduction between 2 groups. Values are mean ± SE.
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A lot of studies have supported the theory that ‘the lower, the better’
with regard to LDL-C [1–3]. To achieve aggressive reduction in LDL-C,
lipid lowering therapy with a statin alone is limited; maximum doses
of statin in clinical practice achieved 70 mg/dL of LDL-C level in Japan.
The combination of a statin and ezetimibe in order to achieve intensive
lipid-lowering can therefore be an attractive therapy considering
the beneﬁcial effects on plaque regression in diabetic patients with
ACS. Furthermore, it is important to establish that plaque response to
LDL-C when adding ezetimibe to a statin in patients with diabetes
differs from that in non-diabetic patients. Recently FDA's Drug Safety
Communication announced that high-dose statins may raise the risk
of diabetes, while, aggressive reduction of the LDL-C levelsmight induce
a greater degree of plaque regression in diabetes patients. To achieve
very low LDL-C level safely, the combination of a statin plus ezetimibe
would be essential.6. Study limitations
The present study has several limitations although the present IVUS
analysis of patients with ACS was pre-speciﬁed in the ZEUS protocol.
First, a 3-year time lag exists between the ZEUS and control patientsA) Non-Diabetes
y=0.065x–8.04 
R=0.114
p=0.38 
B
% change in LDL-C 
%
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Fig. 3. Relationships between% reduction in LDL-C and % change inplaquevolume innon-diabet
and % change in plaque volumewith statin or statin+ ezetimibe treatmentwere observed in n
and % change in plaque volume (PV) in diabetic patients with statin or statin + ezetimibe treathat are being compared. Comprehensive medical therapy has im-
proved with time. Despite the use of same protocol and same analysis
of plaque volume, it is difﬁcult to fully adjust for the differences between
the ZEUS patients and control group and to exclude unknown selection
bias. However, these limitations in the current studywereminimized by
carrying out strict entry criteria. A substantial number of patients were
excluded from the IVUS analysis due to suboptimal image quality and
severe calciﬁcation precluding accurate plaque size assessment and
were also excluded from our accumulated IVUS database due to strict
entry criteria. These strict criteria were likely to have inﬂuenced both
groups equally, however, and were therefore unlikely to have changed
the results.
There is another criticism in which evaluation of a single plaque
of the culprit vessel may not represent pan-coronary characteristics.
Otherwise, ACS may represent the pan-coronary process of vulnerable
plaque, suggesting that a single plaque can reﬂect general feature of
whole coronary artery. Furthermore, it is impossible to perform IVUS
to all coronary arteries for ethical reason because of emergency cases
in this current trial. In this analysis, we set up the primary end point
as a plaque change. The clinical implications of a drug beneﬁt derived
from IVUS remain uncertain. However, we already reported that plaque
regression was correlated with the risk of clinical events.
Compared with statin doses used in Western countries, lower doses
of statins (atorvastatin 20mg) have been shown to have a similar effect) Diabetes
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(atorvastatin 20 mg) [22]. Thus, what may be considered a moderate
statin dose inWestern ACS patientsmay be considered to be a relatively
intensive dose in ACS patients in Japan. Therefore, direct comparisons
between doses used in ACS patients in Western and Japanese studies
may not be possible.
The net efﬁcacy of a statin and ezetimibe in plaque change was not
proved conclusively because there was no prospective randomized
study and no direct comparison of PV between the 2 groups. To validate
this hypothesis and ourﬁndings, especially in diabetic patients, we need
and try the prospective, large-scale, randomized trials as the next step.
7. Conclusion
Early intensive lipid-lowering therapy using atorvastatin or atorva-
statin and ezetimibe in patients after ACS results in remarkable regres-
sion of coronary PV. Additional LDL-C reduction (less than 70 mg/dL)
with ezetimibe and a statin provides no further plaque regression.
However, in diabetic patients, further reduction of LDL-Cwith ezetimibe
and a statin was associated with a signiﬁcantly greater reduction in PV.
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